Prospective Grant of Exclusive License: The Development of Human Therapeutics for the Treatment of Cancer

Resumo

This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent Application 61/241,620 entitled "Development of an Immunotoxin in Which All B-Cell Epitopes Have Been Removed and Which Has High Cytotoxic Activity" [HHS Ref. E-269-2009/0-US-01], US Patent Application 60/969,929 entitled "Deletions in Domain II of Pseudomonas Exotoxin A That Reduce Non-Specific Toxicity" [HHS Ref. E-292-2007/0- US-01], US Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/0-US-01], and all continuing applications and foreign counterparts, to MedImmune, LLC. This license may also include non-exclusive rights to US Patent Application 60/525,371 entitled "Mutated Anti-CD22 Antibodies and Immunoconjugates" [HHS Ref. E-046-2004/0-US-01], US Patent Application 60/325,360 entitled "Mutated Anti-CD22 Antibodies with Increased Affinity to CD22 Expressing Leukemia Cells" [HHS Ref. E-129-2001/0-US- 01], US Patent Application 60/041,437 e